Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 18, 2017; 88 (16 Supplement) April 27, 2017

MIS416, a myeloid targeted immune modulator for the treatment of secondary progressive multiple sclerosis acts directly within the CNS to induce Type I IFN and suppress neuroinflammation (P5.334)

Reza Khorooshi, Vian Wais, Gill Webster, Trevor Owens
First published April 17, 2017,
Reza Khorooshi
1Neurobiology, University of Southern Denmark Odense C Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vian Wais
1Neurobiology, University of Southern Denmark Odense C Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gill Webster
2Innate Immunotherapeutics Auckland New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Trevor Owens
1Neurobiology, University of Southern Denmark Odense C Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
MIS416, a myeloid targeted immune modulator for the treatment of secondary progressive multiple sclerosis acts directly within the CNS to induce Type I IFN and suppress neuroinflammation (P5.334)
Reza Khorooshi, Vian Wais, Gill Webster, Trevor Owens
Neurology Apr 2017, 88 (16 Supplement) P5.334;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To investigate immune-modulatory mechanisms activated directly within the CNS by a novel innate-directed therapy for secondary progressive multiple sclerosis (SPMS).

Background: MIS416 is in a phase 2b placebo controlled efficacy trial for neurological improvement in SPMS patients. Formulated as a microparticle comprising NOD2 and TLR9 ligands, MIS416 enhances endogenous peripheral myeloid anti-inflammatory/tissue repair pathways which crosstalk with the CNS. Importantly, MIS416 may also exert a direct effect within the CNS as it traffics there homeostatically within a discrete subset of blood-derived monocytes. Direct effects of MIS416 within the CNS have not previously been described.

Design/Methods: To determine disease-suppressive effects of MIS416 within the CNS, we used intrathecal injection to cerebrospinal fluid to deliver MIS416 to the brains of mice.

Results: MIS416 induced IFNβ and IFNγ in the CNS of C57BL/6 mice. Mild infiltration of blood-derived myeloid cells was induced, and extraparenchymal leptomeningeal myeloid cells were among the cell sources of IFNβ and IFNγ. RNAseq and RT-qPCR showed induction of IFN-stimulated genes, including IRF7, CCL2, CXCL10, iNOS, and anti-inflammatory IL10.

Mice treated with MIS416 at EAE onset progressed less rapidly than control animals, indicative of disease-suppressive activity. This effect was reduced in mice lacking the Type I IFN receptor, arguing that intra-CNS NOD2- and TLR9-mediated Type I IFN induction may be one mechanism by which MIS416 acts to suppress MS-like disease.

Extraparenchymal myeloid cells phagocytosed fluorescent-tagged MIS416. Fluorescent myeloid cells were also detected in the parenchyma, identified as microglia. MIS416-containing microglia also produced Type I IFN. Mechanisms whereby MIS416 could access microglia to induce IFN include phagocytosis of apoptotic myeloid cells that migrated to parenchyma following phagocytosis of MIS416 in leptomeninges. This is supported by transfer of transgenic reporter cells.

Conclusions: MIS416 can directly activate innate anti-inflammatory programs by CNS-resident myeloid cells, leading to suppression of MS-like disease.

Study Supported by: The Danish Agency for Science, Technology and Innovation; The Danish Multiple Sclerosis Society.

Disclosure: Dr. Khorooshi has nothing to disclose. Dr. Wais has nothing to disclose. Dr. Webster has nothing to disclose. Dr. Owens has nothing to disclose.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (16)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise